IL-PROJECT44
30.4.2021 15:02:11 CEST | Business Wire | Press release
project44, the global leader in advanced visibility for shippers and logistics service providers will expand its real-time shipment tracking services in China – giving clients the same transportation visibility it offers across mature markets like North American and Europe. This expansion will focus the company’s resources on Asia-based visibility to fulfill its vision for global end-to-end visibility across all modes of transportation.
With logistics events in Asia continuing to send shockwaves across western markets, the opacity of Asia’s trucking markets has emerged as a weak link in global supply chains. As the economic recovery picks up pace, global supply chains are under pressure to improve agility, predictability, and efficiency.
At the same time, truckload markets in Asia have been modernizing rapidly as old trucks go out of service and China continues to incentivize the scrapping of old trucks. Newer trucks are equipped with electronic logging devices, paving the way to connect these trucks (with necessary data privacy provisions) to supply chain networks. These developments allow project44 to provide the foundational data needed to translate early indicators into important levers for supply chain resiliency.
Industry Support
The move by project44 to ramp up visibility in China has garnered broad support across the industry:
“Over the past year, Gartner has seen a dramatic increase in interest for Real-Time Transportation Visibility (RTTV) in the Asia Pacific,” said Bart A. De Muynck, Research Vice President, Transportation Technology at Gartner. “The sheer size of the Asia Pacific region combined with the diverse cultures spread across it creates unique challenges for transportation. Organizations that operate complex global supply chains often favor visibility solutions that can be implemented and utilized worldwide. project44 is recognized as a Leader by Gartner for its strong presence in both North America and Europe. Enterprise shippers that operate in Asia will benefit from project44’s expanded carrier coverage in China.”
“Building a more predictable global supply chain to increase on-time delivery and customer satisfaction is key to Lenovo’s business strategy,” said Renée Ure, Chief Operating Officer, Lenovo Infrastructure Solutions Group. “It’s critical to understand when materials are arriving from our suppliers to our factories across the world. project44’s expansion into the Asia Pacific region will give us further end-to-end visibility into our global supply chain to help us deliver on our promises to our customers.”
"CNHi is a truly global company in 180 countries. The recent state of global transportation has proven challenging, in part because it is difficult to manage our supply chains that span so many countries when disruption is high and visibility is so fragmented," said Dror Noach, Vice President of Global Logistics, CNH Industrial. "Gaining better visibility of both domestic and inbound flows going into our Asian manufacturing plants, especially China, could be quite beneficial for us. We believe project44's efforts to expand coverage in this region can help us improve assurance of supply and increase our efficiency."
Expanded Global Network Coverage
project44's best-in-class network already connects truckload carriers on every continent and nearly all containerized ocean freight moving between them, however, getting visibility into Asia’s trucking market remains a challenge for shippers. Its increased focus on Asian markets allows project44 to increase saturation outside of mature transportation markets and into Asia's ground transportation networks.
“At project44 we want to be wherever our customers need us, which means being connected to carriers all over the globe. For the first time ever, shippers can have a true global view of their supply chain network in a single platform,” said Jett McCandless, CEO and Founder of project44. “With our expansion into the Asia Pacific, we are considering the capabilities, regulations, and intricacies within each country which is key to delivering value to our current and future customers."
By expanding visibility in Asian markets, project44 will help buyers of Asian goods increase the resiliency of their supply chains. And in the process, project44 will extend visibility to domestic Asian shippers and logistics service providers who demand the same real-time transportation visibility enjoyed in western markets.
About project44
project44 solves some of the world’s most critical logistics challenges by connecting, automating, and providing real-time visibility into global transportation processes. With project44’s cloud-based platform, organizations can increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional, Amazon-like experience to their customers. project44 supports all transportation modes and shipping types, including air, parcel, final-mile, less-than-truckload, volume less-than-truckload, groupage, truckload, rail, intermodal, and ocean. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
